Dentsply Sirona

XRAY

Market cap $2.41B

XRAY bets on digital workflows and R&D expansion to fuel growth, but forex pressure and weak Europe demand cloud its near-term outlook.

Gregory Lucier acquired 15,000 shares for a total of approximately ~$187,000 on March 9, 2026. No direct holdings were involved in the transaction; all shares are held indirectly via trusts or similar entities.

Dentsply Sirona and Siemens Healthineers win FDA clearance for the first dental-dedicated MRI designed to improve soft-tissue dental imaging and diagnostics.

DENTSPLY SIRONA Inc. (XRAY) Presents at Leerink Global Healthcare Conference 2026 Transcript

Pharmaceutical outfit Pfizer offers the highest dividend yield to newcomers. Dentsply Sirona, however, will likely produce the fastest dividend growth.

Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI 1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial 2 validating the system's significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology's applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning.

CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST.

Review Dentsply's (XRAY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.